Inhibition of VEGFR, MET, and other tyrosine kinases including the TAM family of kinases (TYRO3, AXL, and MER) by cabozantinib reduces the potential for tumour growth and creates an immune-permissive tumour microenvironment6,18; PD-1/PD-L1 inhibition by atezolizumab has been shown to reverse T-cell suppression.19 This evidence concerns the gene PDCD1 and neoplasm.